[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Re: Powernet: International Agency for Research on Cancer (I
The first time this message was posted to radsafe it included an attached
WP file. That file appeared scrambled. Please ignore the mess. The
entire text of the announcement is found below...
United States Commercial Nuclear Power Reactor Participation in the Ongoing
Cancer Mortality Study Conducted by the International Agency for Research
on Cancer (IARC)
January 20, 2000
Dear Colleague,
A substantial segment of the United States commercial nuclear power industry
has agreed to participate in an ongoing international epidemiological study
on radiation and cancer mortality in nuclear workers. The primary purpose
for industry participation in the study is to better understand the risks
associated with occupational exposure to ionizing radiation at commercial
nuclear power plants. U.S. commercial participation in the ongoing study
will involve 15 nuclear utilities, 55 reactors, and include data on an
estimated 70,000 radiation workers.
The ongoing study is a combined mortality study of nuclear workers in
seventeen countries (the International Collaborative Study of Cancer Risk
Among Radiation Workers in the Nuclear Industry) being conducted by the
International Agency for Research on Cancer (IARC), a research agency of
the World Health Organization. The study was begun in 1993, with completion
scheduled for 2001 and issuance of a report by IARC targeted for 2001.
The International Collaborative Study, headed by IARC's Dr. Elisabeth
Cardis, includes over 500,000 radiation workers worldwide, in addition to
the U.S. commercial cohort. The IARC study is designed as a retrospective
pooled cancer mortality study. IARC has stated that the primary objective
of the international study is to better estimate the radiation-related risk
of cancer and leukemia mortality following low-dose protracted exposures.
Specifically, the IARC study is intended to provide data on low dose
chronic exposures for comparison with the risk estimates derived from
studies of persons having received acute high dose exposures. These data,
in turn, are intended to provide a test of the extrapolation models
currently used by various scientific bodies and government agencies for
estimating radiation risks and for setting radiation protection standards.
The inclusion of the U.S. commercial worker data in the IARC study is being
directed by Dr. Geoffrey R. Howe, a distinguished epidemiologist and Gelman
Professor of Public Health at Columbia University in New York. Dr. Howe has
conducted many national and international studies of radiation and cancer
including previous studies of radiation workers. Battelle Pacific Northwest
National Laboratory, along with other Battelle research centers will
assemble dosimetry and demographic data under the guidance of Dr. Howe. The
Battelle team Project Manager is Jack Fix, CHP. The utility-provided data
will undergo analysis and quality assurance by Dr. Howe, the Battelle team
as well as the IARC investigators. The utilities will have no control over
the data, analyses, or the independent report that is issued by IARC.
The cost of providing the data on U.S. commercial nuclear workers to the
IARC study will be borne by the participating utilities. The co-ordination
of the International Collaborative Study is supported by the European
Commission and by several organizations in participating countries; the
cost of the national study in each country is covered by national funding
bodies, participating facilities and a number of national and public
institutions.
Dr. Howe, Battelle, and all utility participants are committed to
collecting and maintaining the data in a manner designed to ensure
confidentiality. In addition, although the participating utilities are
providing worker information to the independent scientific group for use
with the National Death Index, no such correlated information will be
returned to the participating utilities. The participating utilities are
informing their workers about the study, including issues of
confidentiality and privacy.
Inquiries regarding the study may be directed to the following individuals
for the respective areas of interest.
Independent Scientific Study Group
Geoffrey R. Howe, PhD Overall Study and Epidemiology 212.305.4601
Jack Fix, CHP Dosimetry 509.375.2512
Study Project Manager
Roger P. Shaw, CHP Administrative 973.622.4444
Chairman, Utility Steering Committee
Michael J. Slobodien, CHP Administrative 609.971.4709
Please feel free to call upon us should you desire any additional
information.
Respectfully,
/s/
Roger P. Shaw
Study Project Manager
(973) 622-4444
************************************************************************
The RADSAFE Frequently Asked Questions list, archives and subscription
information can be accessed at http://www.ehs.uiuc.edu/~rad/radsafe.html